Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier
- PMID: 22230573
- DOI: 10.1016/B978-0-12-396962-0.00011-2
Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier
Abstract
Recombinant protein therapeutics cannot enter brain drug development because these large molecule drugs do not cross the blood-brain barrier (BBB). However, recombinant proteins can be reengineered as BBB-penetrating IgG fusion proteins, where the IgG part is a genetically engineered monoclonal antibody (MAb) against an endogenous BBB receptor, such as the human insulin receptor (HIR) or the transferrin receptor (TfR). The IgG binds the endogenous insulin receptor or TfR to trigger transport across the BBB and acts as a molecular Trojan horse (MTH) to ferry into brain the fused protein therapeutic. The most potent MTH to date is a MAb against the HIR, designated the HIRMAb, which is active in humans and Old World primates, such as the Rhesus monkey. There is no known MAb against the mouse insulin receptor. For drug delivery in the mouse, protein therapeutics are fused to a chimeric MAb against the mouse TfR, designated the cTfRMAb. The HIRMAb or cTfRMAb Trojan horses have been engineered and expressed as fusion proteins with multiple classes of protein therapeutics, including lysosomal enzymes, neurotrophins, decoy receptors, single chain Fv therapeutic antibodies, and avidin. The pharmacokinetic (PK) properties of the IgG fusion proteins differ from that of typical MAb drugs and resemble the PK profiles of small molecules due to rapid uptake by peripheral tissues, as well as brain. The brain uptake of the IgG fusion proteins, 2-3% of injected dose/brain, is comparable to the brain uptake of small molecules. The IgG fusion proteins have been administered chronically in mouse models, and the immune response is low titer and has no effect on the fusion protein clearance from blood or brain uptake in vivo. The BBB MTH technology enables the reengineering of a wide spectrum of recombinant protein therapeutics for targeted drug delivery to the brain.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.J Drug Target. 2012 Sep;20(8):715-9. doi: 10.3109/1061186X.2012.712132. J Drug Target. 2012. PMID: 22845843
-
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.Biotechnol Bioeng. 2008 Feb 1;99(2):475-84. doi: 10.1002/bit.21602. Biotechnol Bioeng. 2008. PMID: 17680664
-
Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.Biotechnol Bioeng. 2007 Aug 15;97(6):1376-86. doi: 10.1002/bit.21369. Biotechnol Bioeng. 2007. PMID: 17286273
-
Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.Bioconjug Chem. 2008 Jul;19(7):1327-38. doi: 10.1021/bc800148t. Epub 2008 Jun 12. Bioconjug Chem. 2008. PMID: 18547095 Review.
-
A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.Drug News Perspect. 2008 Nov;21(9):489-503. doi: 10.1358/dnp.2008.21.9.1290820. Drug News Perspect. 2008. PMID: 19180267 Review.
Cited by
-
Advances in Antibody-Based Therapeutics for Cerebral Ischemia.Pharmaceutics. 2022 Dec 31;15(1):145. doi: 10.3390/pharmaceutics15010145. Pharmaceutics. 2022. PMID: 36678774 Free PMC article. Review.
-
Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review.IET Nanobiotechnol. 2023 May;17(3):154-170. doi: 10.1049/nbt2.12127. Epub 2023 Mar 22. IET Nanobiotechnol. 2023. PMID: 36949020 Free PMC article. Review.
-
Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.Mol Pharm. 2014 Aug 4;11(8):2928-34. doi: 10.1021/mp500258p. Epub 2014 Jun 26. Mol Pharm. 2014. PMID: 24949884 Free PMC article.
-
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain.Front Aging Neurosci. 2020 Jan 10;11:373. doi: 10.3389/fnagi.2019.00373. eCollection 2019. Front Aging Neurosci. 2020. PMID: 31998120 Free PMC article.
-
Microbubble gas volume: A unifying dose parameter in blood-brain barrier opening by focused ultrasound.Theranostics. 2017 Jan 1;7(1):144-152. doi: 10.7150/thno.15987. eCollection 2017. Theranostics. 2017. PMID: 28042323 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous